Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), the AIM-listed medical imaging company, will have its Xenon-based magnetic resonance imaging (MRI) technology showcased in more than 30 clinical studies at the American Thoracic Society’s annual meetings in San Francisco this month.
The company, which develops imaging platforms designed to assess lung function, has been selected as a featured participant at the ATS Respiratory Innovation Summit, taking place on 16–17 May. It will also be present at the society’s International Conference from 18–21 May.
The prominence of Xenon MRI at both events reflects growing clinical and research interest in the technology’s ability to provide functional imaging of the lungs.
Presentations at the conference will include research from more than 10 clinical sites, covering conditions such as asthma, chronic obstructive pulmonary disease, cystic fibrosis and pulmonary arterial hypertension, as well as COVID-19 and post-transplant monitoring.
Polarean said the technology is increasingly being used in both clinical practice and drug development. Company representatives will attend the conferences to meet with clinicians, researchers and potential industry partners.
CEO Christopher von Jako said: "We are honoured to return as a featured company at the Respiratory Innovation Summit.
"RIS and the ATS International Conference provide vital opportunities to engage with thought leaders, strengthen partnerships, and highlight the growing body of clinical evidence supporting Xenon MRI.
"With over 30 presentations this year, it's clear that Xenon MRI is not only gaining traction - it's shaping the future of functional lung imaging and respiratory care."